Oncolytics Biotech Inc.  

(Public, TSE:ONC)   Watch this stock  
Find more results for ONC
1.70
-0.02 (-1.16%)
Apr 22 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.70 - 1.74
52 week 1.54 - 3.62
Open 1.71
Vol / Avg. 9,312.00/51,268.00
Mkt cap 144.17M
P/E     -
Div/yield     -
EPS -0.28
Shares 84.80M
Beta 1.43
Inst. own     -
Apr 8, 2014
ONCOLYTICS BIOTECH INC at Needham Healthcare Conference
Apr 8, 2014
Oncolytics Biotech Clinical Update Conference Call
Mar 13, 2014
Q4 2013 ONCOLYTICS BIOTECH INC Earnings Release
Mar 5, 2014
ONCOLYTICS BIOTECH INC at Cowen Health Care Conference - Webcast
Feb 26, 2014
ONCOLYTICS BIOTECH INC Conference Presentation at 2014 RBC Capital Markets Global Healthcare Conference - Webcast
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -76.46% -93.57%
Return on average equity -93.22% -127.20%
Employees 25 -
CDP Score - -

Address

210, 1167 Kensington Crescent, N.W.
CALGARY, AB T2N 1X7
Canada
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links

Description

Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. As of December 31, 2011, the United States National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) were sponsoring part of its clinical trial program. Oncolytics uses contract toll manufacturers to produce REOLYSIN.

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Kirk J. Look Chief Financial Officer
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
George M. Gill M.D. Senior Vice President - Clinical and Regulatory Affairs
Alan J Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 66
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Robert B. Schultz Lead Independent Director
Wayne F. Pisano Director
Jim Dinning Independent Director
Age: 60
Edwin Levy Ph.D. Independent Director